Related Experiment Video

Updated: Oct 13, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

[Clinical evaluation of cefotetan in pediatrics]

K Yanagisawa, H Hoshina, H Ichihashi

    The Japanese Journal of Antibiotics
    |June 1, 1983
    PubMed

    Insights

    Cefotetan (CTT), a novel cephamycin antibiotic, demonstrated a 68.8% efficacy rate in treating moderate to severe pediatric infections. CTT was well-tolerated, with minimal adverse effects observed in the study population.

    Area of Science:

    • Infectious Diseases
    • Pharmacology
    • Pediatrics

    Context:

    • Cefotetan (CTT) is a new cephamycin antibiotic.
    • Pediatric patients aged 1 year 1 month to 9 years with moderate or severe infections were included.
    • The study evaluated CTT's efficacy and safety in a pediatric population.

    Purpose:

    • To assess the clinical efficacy and safety of Cefotetan (CTT) in pediatric patients.
    • To determine the effectiveness of CTT against various bacterial infections in children.
    • To identify any adverse effects associated with CTT administration in pediatric patients.

    Summary:

    • Twenty-one pediatric patients received intravenous CTT at daily doses of 26.5 to 120 mg/kg for 2 to 14 days.
    • Clinical efficacy was evaluated in 16 patients, with a good response in 11 (68.8%), fair in 1, and poor in 4.
    • Pathogen eradication was observed for H. influenzae and K. pneumoniae, while S. faecalis persisted; one case of eosinophilia was noted as the only adverse effect.

    Impact:

    • Cefotetan (CTT) shows significant potential as an effective antibiotic for treating serious infections in pediatric patients.
    • The favorable safety profile suggests CTT can be a valuable therapeutic option in pediatric infectious disease management.
    • Further research may explore CTT's role in combating specific resistant bacterial strains in children.

    More Related Videos

    Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

    Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

    Published on: January 22, 2021

    Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates08:32

    Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates

    Published on: February 17, 2023

    Related Concept Videos

    Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

    Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

    Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...